The Biobank Integrating Longitudinal ERCP Within a Prospective Chronic Pancreatitis Cohort

Evaluated by scores from the pancreatic exocrine insufficiency questionnaire. The calculated final score ranges from 0 to 4. Higher scores indicate more severe symptoms and worse pancreatic exocrine function.

Evaluated by documenting the number of participants who experience at least one unplanned hospital readmission related to chronic pancreatitis and its complications within the follow-up period.

Evaluated by documenting the number of participants who develop pancreatic cancer during the follow-up period. The diagnosis is clinically confirmed based on abdominal imaging, specific tumor markers, and/or pathological evaluation.

Evaluated using abdominal MRI/MRCP based on the Cambridge classification system. The Cambridge classification grades the severity of chronic pancreatitis based on features such as ductal dilation, strictures, stones, and parenchymal changes. The structural severity is typically graded as normal, equivocal, mild, moderate, or severe. A worse grade indicates more advanced morphological changes.

Evaluated by documenting the number of participants who exhibit at least one of the following specific features on abdominal CT: pancreatic parenchymal calcification, solid masses, suspected malignant lesions, peripancreatic exudation or fluid collection, vascular complications, or progression of pancreatic fibrosis.

Evaluated by documenting the number of participants who undergo one or more specific Endoscopic Retrograde Cholangiopancreatography (ERCP) therapeutic interventions during the follow-up period.

Evaluated by documenting the number of participants who exhibit specific microstructural changes in the pancreatic parenchyma and pancreatic ducts using Endoscopic Ultrasound (EUS).

Evaluated using a standardized digital TCM instrument, which quantitatively analyzes clinical data to generate scores for 9 standard TCM constitutions. Each of the 9 constitutions is scored on a scale ranging from 0 to 100. Higher scores indicate a stronger inclination toward that specific constitution type.

Evaluated by documenting the number of participants who exhibit clinically significant abnormal values in routine blood biochemistry tests during the follow-up period. The comprehensive monitoring panel includes liver and kidney function, electrolytes, bilirubin, blood lipids, inflammatory markers, and pancreatic enzymes.

Description: Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The total score ranges from 0 to 21. Higher scores indicate worse sleep quality and more severe sleep disturbances.

A continuous glucose monitoring system is used to assess glucose fluctuations within the target range.

Gastrointestinal Symptom Rating Scale (GSRS) is used to Core assess the symptoms associated with chronic pancreatitis. The GSRS total score ranges from 15 to 105. Higher scores indicate more severe gastrointestinal symptoms

Quality of life will be assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. The index score typically ranges from less than 0 to 1. Higher scores indicate a better health-related quality of life.

Patients' anxiety levels will be assessed using the Generalized Anxiety Disorder 7-item (GAD-7) scale. The total score ranges from 0 to 21. Higher scores indicate more severe symptoms of anxiety.

Record the frequency, duration, severity, and treatment outcomes of the patient's acute exacerbations.

Assess the incidence of adverse events, such as postoperative pancreatitis, biliary tract infection, gastrointestinal bleeding, and perforation occurring within 30 days after ERCP.

Evaluated by analyzing microbiome and specific fungal culture data from samples. The outcome measures the quantitative shift in the relative abundance of targeted microbiota communities.

Pancreatic endocrine function will be evaluated by measuring the percentage of HbA1c in the blood. Higher values indicate poorer long-term glycemic control.

Endocrine function will be evaluated by assessing fasting blood glucose levels. Higher values indicate impaired glucose metabolism or insulin resistance.

Endocrine function will be evaluated by measuring fasting serum insulin levels. Abnormal levels can indicate insulin resistance or impaired pancreatic beta-cell function.

Endocrine function will be evaluated by assessing serum C-peptide levels. C-peptide serves as a reliable biomarker for endogenous insulin production, with lower values indicating decreased pancreatic beta-cell secretory function.

Endocrine function will be evaluated by measuring serum glucagon levels, a hormone produced by pancreatic alpha cells. Abnormal levels reflect dysregulation in glucose counter-regulation.

Endocrine function will be evaluated by measuring serum somatostatin levels, a hormone produced by pancreatic delta cells that regulates the broader endocrine and digestive systems.

Pancreatic exocrine function will be evaluated by assessing fecal elastase-1 levels. Concentrations below 200 µg/g typically indicate pancreatic exocrine insufficiency (PEI), with lower values reflecting more severe insufficiency.

Pancreatic exocrine function and secondary nutritional status will be evaluated by measuring the serum concentrations of fat-soluble vitamins (e.g., Vitamins A, D, E, and K). Lower values indicate potential fat malabsorption due to exocrine insufficiency.

Evaluated by calculating the total direct medical costs incurred by participants due to unplanned hospital readmissions related to chronic pancreatitis.

Evaluated by documenting the number of participants who require surgical, endoscopic, or other interventional treatments during their unplanned readmission for chronic pancreatitis.

Patients' depression levels will be assessed using the Patient Health Questionnaire-9 (PHQ-9). The total score ranges from 0 to 27. Higher scores indicate more severe symptoms of depression.

Evaluated using metabolomics profiling to measure the shift in the concentration of specific metabolite biomarkers.

Evaluated by integrating high-dimensional multi-omics data derived from multiple biological samples. Advanced statistical modeling, such as LASSO regression and multivariable Cox proportional hazards models, will be applied to construct a composite multi-omics risk signature associated with chronic pancreatitis. The outcome is reported as a continuous multi-omics risk score. Higher scores indicate a greater risk of disease progression and worse clinical outcomes.